Education
About Us
Working with TipRanks
Follow Us
Oculis Holding Ag (OCS)
:OCS
OCS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.79 - $23.08
Previous CloseN/A
Volume95.89K
Average Volume (3M)48.31K
Market Cap
$860.64M
Enterprise Value$619.50M
Total Cash (Recent Filing)CHF46.28M
Total Debt (Recent Filing)CHF114.27M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 08, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding48,000,000
10 Day Avg. Volume63,446
30 Day Avg. Volume48,311
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)854.93
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.80Price Target Upside77.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Oculis Holding News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessOCS-05 recently demonstrated positive Ph2 data both in terms of safety and efficacy and showed positive structural and functional improvements in retinal thickness and vision metrics.
Financial PositionThe recently completed $100m equity financing extends Oculis's cash runway into early 2028.
Regulatory ProgressOculis now has alignment with the FDA on a precision medicine-based development approach for OCS-02, leveraging biomarker-driven patient selection.
Bears Say
Clinical Trial RisksRisks include possible failure of OCS-01 or OCS-02 in clinical trials or to secure regulatory approval, as well as potential dilution risk.
Development DelaysOculis fine-tuned its timing for phase 3 DIAMOND trial readout in diabetic macular edema to 1H26 vs. prior estimate of 2H25.
---
Ownership Overview
―
Insiders
0.03% Mutual Funds
0.18% Other Institutional Investors
99.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OCS FAQ
What was Oculis Holding Ag’s price range in the past 12 months?
Oculis Holding Ag lowest stock price was $10.79 and its highest was $23.08 in the past 12 months.
What is Oculis Holding Ag’s market cap?
Oculis Holding Ag’s market cap is $860.64M.
When is Oculis Holding Ag’s upcoming earnings report date?
Oculis Holding Ag’s upcoming earnings report date is May 08, 2025 which is in 21 days.
How were Oculis Holding Ag’s earnings last quarter?
Oculis Holding Ag released its earnings results on Mar 11, 2025. The company reported -$0.819 earnings per share for the quarter, missing the consensus estimate of -$0.564 by -$0.255.
Is Oculis Holding Ag overvalued?
According to Wall Street analysts Oculis Holding Ag’s price is currently Undervalued.
Does Oculis Holding Ag pay dividends?
Oculis Holding Ag does not currently pay dividends.
What is Oculis Holding Ag’s EPS estimate?
Oculis Holding Ag’s EPS estimate is -0.52.
How many shares outstanding does Oculis Holding Ag have?
Oculis Holding Ag has 48,000,000 shares outstanding.
What happened to Oculis Holding Ag’s price movement after its last earnings report?
Oculis Holding Ag reported an EPS of -$0.819 in its last earnings report, missing expectations of -$0.564. Following the earnings report the stock price went up 2.391%.
Which hedge fund is a major shareholder of Oculis Holding Ag?
Currently, no hedge funds are holding shares in OCS
---
Oculis Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.80 (77.36% Upside)
$31.80 (77.36% Upside)
Hedge Fund Trend
Decreased
By 663.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.16%
12-Months-Change
Fundamentals
Return on Equity
-101.29%
Trailing 12-Months
Asset Growth
-2.26%
Trailing 12-Months
Company Description
Oculis Holding Ag
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
---
OCS Stock 12 Month Forecast
Average Price Target
$31.80
▲(77.36% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Anavex Life Sciences
―
Mineralys Therapeutics, Inc.
―
Bicara Therapeutics Inc.
―
Best Analysts Covering OCS
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+20.71%
reiterated a buy rating 18 hours ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +20.71% per trade.
---